Paper42820177PubMed
Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.
Alghulayqah AI. Cureus, 2026.
Cite this record
ConductScience Library. Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report. Papers, record 42820177. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42820177
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.
- Journal
- Cureus
- Year
- 2026
- Publication types
- Case Reports, Journal Article
- Revised in PubMed
- 2026-10-01
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26400368 | Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. | Respir Res | 2015 | https://conductscience.org/library/papers/26400368 | PubMed |
| 2 | 22689825 | VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. | J Exp Med | 2012 | https://conductscience.org/library/papers/22689825 | PubMed |
| 3 | 37414756 | Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37414756 | PubMed |
| 4 | 20935110 | Clinical course and prediction of survival in idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/20935110 | PubMed |
| 5 | 34289823 | Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. | BMC Pulm Med | 2021 | https://conductscience.org/library/papers/34289823 | PubMed |
| 6 | 30841014 | Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis. | Tuberc Respir Dis (Seoul) | 2019 | https://conductscience.org/library/papers/30841014 | PubMed |
| 7 | 31016670 | Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31016670 | PubMed |
| 8 | 17519900 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17519900 | PubMed |
| 9 | 28870253 | Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. | J Hematol Oncol | 2017 | https://conductscience.org/library/papers/28870253 | PubMed |
| 10 | 7249508 | A method for estimating the probability of adverse drug reactions. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7249508 | PubMed |
| 11 | 12209733 | Severe periorbital edema secondary to STI571 (Gleevec). | Cancer | 2002 | https://conductscience.org/library/papers/12209733 | PubMed |
| 12 | 36087188 | Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. | Target Oncol | 2022 | https://conductscience.org/library/papers/36087188 | PubMed |
| 13 | 25496490 | Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. | Respir Res | 2014 | https://conductscience.org/library/papers/25496490 | PubMed |
| 14 | 24836310 | Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24836310 | PubMed |
| 15 | 33765296 | Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. | Drugs | 2021 | https://conductscience.org/library/papers/33765296 | PubMed |
| 16 | 21471066 | An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21471066 | PubMed |
| 17 | 25745043 | Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. | Eur Respir J | 2015 | https://conductscience.org/library/papers/25745043 | PubMed |
| 18 | 32759374 | Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. | Eur Respir Rev | 2020 | https://conductscience.org/library/papers/32759374 | PubMed |
| 19 | 25946646 | Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. | Pharmacol Ther | 2015 | https://conductscience.org/library/papers/25946646 | PubMed |
| 20 | 19689244 | Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. | Curr Drug Metab | 2009 | https://conductscience.org/library/papers/19689244 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42820177
GET https://conductscience.org/api/papers/v1/42820177/references?page=2